Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. - Concepedia

Concepedia

Publication | Closed Access

Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.

74

Citations

19

References

1996

Year

Stephen Clarke, Janet Hanwell, M. de Boer, AS Planting, Jaco J. Verweij, Morton Walker, Robert P. Smith, A L Jackman, L. R. HUGHES, K.R. Harrap,

Journal of Clinical Oncology

Abstract

The dose of ZD1694 recommended for phase II trials is 3.0 mg/m2.

References

	Year	Citations

Page 1